Clinical trials: Adjuvant Treatment
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the…
- Trial name
- NCT04634877
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 990 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Bacterial Vaginosis (BV), Recurrent Bacterial Vaginosis
Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.
This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.
- Trial name
- Vagitab (NCT06725888)
- Testing
- Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- S.I.I.T. Srl
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Clear Cell Renal Carcinoma
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
- Trial name
- ATLAS (NCT01599754)
- Testing
- Axitinib
- Where
- 106 sites in United States, China and 7 more
- Volunteers
- 724 people
- Sponsor
- SFJ Pharma Ltd. II
To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer
This randomized, double-blind, multicenter, placebo-controlled Phase II trial was designed to investigate the efficacy and safety of GM1 in the prevention of peripheral neuropathy caused by albumin-bound paclitaxel regimen in…
- Trial name
- NCT05802342
- Testing
- Monosialotetrahexose ganglioside sodium injection
- Volunteers
- 150 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast…
- Trial name
- EarLEE-1 (NCT03078751)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Malignant Melanoma
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
- Trial name
- NCT00601861
- Testing
- recombinant interleukin-21
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Novo Nordisk A/S
Breast Cancer
Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue
The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.
- Trial name
- NCT00555841
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sigma-Tau Research, Inc.
Breast Cancer, Letrozole
Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients
Title of study: An observational, multicenter study on the safety and efficacy of Femara® (Letrozole) as an extended adjuvant treatment in breast cancer patients who completed adjuvant Tamoxifen or Toremifen treatment Objectives…
- Trial name
- NCT01249456
- Where
- South Korea
- Volunteers
- 392 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m^2 or Taxol 175 mg/m^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy.
- Trial name
- NCT00394251
- Testing
- Adriamycin and Cytoxan (AC), ABI-007, Taxol
- Where
- 27 sites in United States
- Volunteers
- 197 people
- Sponsor
- Celgene
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Prostatic Neoplasms
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy.
- Trial name
- NCT00283062
- Testing
- Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 228 people
- Sponsor
- Sanofi
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
The aim of this observational study is to document the efficacy and tolerability of high-dose interferon therapy in adult participants with malignant melanoma at high risk of relapse and to compare them with the survival times…
- Trial name
- NCT00749684
- Testing
- Interferon α-2b
- Volunteers
- 138 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer
This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in…
- Trial name
- NCT00269152
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients.
- Trial name
- MINT (NCT01501487)
- Testing
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- Where
- 9 sites in United States
- Volunteers
- 226 people
- Sponsor
- Agendia
HER2-positive Carcinoma of Breast
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy.
- Trial name
- NCT02162667
- Testing
- Trastuzumab
- Where
- 98 sites in Argentina, Belarus and 20 more
- Volunteers
- 562 people
- Sponsor
- Celltrion
Melanoma, Adjuvant
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- NCT04544202
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
To explore the survival benefit of the gefitinib combined with radiotherapy as adjuvant therapy for completely resected patients with Pathological stage IIIA-N2 NSCLC harbouring sensitive mutations of EGFR.
- Trial name
- NCT03381430
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.